Table 1 Clinical data of the patients included in the study as well as for patients with low or high preoperative IL-8 values

Age (mean + range)

60 (28–82)

58 (28–79)

61 (35–82)

0.41

Sex f/m (f%/m%)

19/30 (39%/61%)

9/14 (39%/61%)

10/14 (42%/58%)

0.53

ASA

 I

1 (2%)

1 (4%)

0 (0%)

0.86

 II

14 (29%)

6 (26%)

8 (33%)

 III

34 (69%)

16 (70%)

16 (67%)

Tumor stage

 T1

1 (2%)

1 (4%)

0 (0%)

0.69

 T2

9 (18%)

4 (17%)

4 (17%)

 T3

34 (69%)

15 (65%)

18 (78%)

 T4

5 (10%)

3 (13%)

2 (9%)

Lymph nodes

 N0

20 (41%)

10 (43%)

10 (43%)

0.84

 N1

15 (31%)

7 (30%)

6 (26%)

 N2

14 (29%)

6 (26%)

8(35%)

Grading

 G1

1 (2%)

1 (4%)

0 (0%)

0.31

 G2

19 (39%)

11 (48%)

7(30%)

 G3

7 (14%)

2 (9%)

5 (22%)

 Gx

22 (45%)

9 (39%)

12 (52%)

Resection

 R0

44 (90%)

21 (91%)

21 (88%)

0.40

 R1

2 (4%)

1 (4%)

1 (4%)

 R2

2 (4%)

0

2 (8%)

 Rx

1 (2%)

1 (4%)

0

Synchronous Metastases

34 (69%)

15 (65%)

18 (75%)

0.52

Open surgery

44 (90%)

19 (83%)

23 (96%)

0.14

Laparoscopic surgery

5 (10%)

4 (17%)

1 (4%)

0.14

Resection

0.75

 Wedge

15 (31%)

6 (26%)

7 (29%)

 Segment

20 (41%)

10 (43%)

10 (42%)

 HH

14 (29%)

7 (30%)

7 (29%)

Neoadj.Chemo

23 (47%)

11 (48%)

10 (42%)

0.87

No complication

31 (63%)

8 (35%)

9 (37%)

0.85

Complications

18 (37%)

15 (65%)

15 (63%)

0.85

Clavien Dindo

0.43

 CD I

2 (4%)

0

2 (4%)

 CD II

6 (12%)

4 (17%)

2 (12%)

 CD IIIa

6 (12%)

3 (13%)

2 (8%)

 CD IIIb

4 (8%)

1 (4%)

3 (8%)

 CD IV

0 (0%)

0 (0%)

0 (0%)

 CD V

0 (0%)

0 (0%)

0 (0%)

Days ICU mean (min–max)

1.4 (0–10)

1.4 (0–6)

1.5 (0–10)

0.83

Days hospitalized (min–max)

10.3 (3–49)

11.2 (3–49)

9.5 (4–28)

0.98

Median follow up (months)

36

36

24

Relapsed during follow up

39 (80%)

18 (78%)

20 (83%)

0.66

Died during follow up

28 (57%)

11 (48%)

16 (67%)

0.19

CEA > 60

6

3

3

0.73

Other Mets than liver

16

6

10

0.26

Largest Met > 4 cm

14

6

8

0.59

≥ 3 Livermets

27

13

14

0.90